Unlike December of 2015, though -- the bank has also dropped the hammer, on Mr. Ian Read, and Pfizer -- making it an "Equal Weight", with a new $3 haircut -- on the price target (as detailed at right). Barclay's says it is less likely now that Pfizer will undergo a "transformative" mega-deal. So it is clipping the stock's wings (even though that $38. . . is above current NYSE trading prices).
Here is a bit from CNBC on it all:
. . . .Analyst Geoff Meacham and his team also raised their price target on Merck by $2 to $64, a more than 17 percent increase from Wednesday's close.
"In our view, there is perhaps 15 to 20 percent of first-line lung market share 'up for grabs' in the U.S.," the analysts said in a note to investors Thursday. Meacham also noted a better outlook versus key competitors, namely Bristol-Myers Squibb.
Merck shares rose 1.1 percent Thursday above $55 a share. The stock has fallen 3 percent this year. . . .
Now you know. Great news, for Merckies! And do get out and breathe that emerging spring air -- I am off to do so -- and find a food truck with lobster rolls (or gumbo), right now! Smiling widely, at "Miss Calypso". . . . (of one year ago).
नमस्ते
No comments:
Post a Comment